Does stress induce bowel dysfunction?

References

• Thompson WG. The irritable colon. CMAJ 1974;111(11):1236, 1241-1234
   PubMed Web of Science ®Google Scholar
• Martinez V, Wang L, Rivier JE, et al. Differential actions of peripheral corticotropin-releasing factor (CRF), urocortin II, and urocortin III on gastric emptying and colonic transit in mice: role of CRF receptor subtypes 1 and 2. J Pharmacol Exp Ther 2002;301(2):611-17
   PubMed Web of Science ®Google Scholar
• Kihara N, Fujimura M, Yamamoto I, et al. Effects of central and peripheral urocortin on fed and fasted gastroduodenal motor activity in conscious rats. Am J Physiol Gastrointest Liver Physiol 2001;280(3):G406-19
   Web of Science ®Google Scholar
• Czimmer J, Million M, Tache Y. Urocortin 2 acts centrally to delay gastric emptying through sympathetic pathways while CRF and urocortin 1 inhibitory actions are vagal dependent in rats. Am J Physiol Gastrointest Liver Physiol 2006;290(3):G511-18
   Web of Science ®Google Scholar
• Soderholm JD, Yates DA, Gareau MG, et al. Neonatal maternal separation predisposes adult rats to colonic barrier dysfunction in response to mild stress. Am J Physiol Gastrointest Liver Physiol 2002;283(6):G1257-63
   Web of Science ®Google Scholar
• Zheng G, Wu SP, Hu Y, et al. Corticosterone mediates stress-related increased intestinal permeability in a region-specific manner. Neurogastroenterol Motil 2013;25(2):e127-39
   Web of Science ®Google Scholar
• Dunlop SP, Hebden J, Campbell E, et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006;101(6):1288-94
   PubMed Web of Science ®Google Scholar
• Vanuytsel T, van Wanrooy S, Vanheel H, et al. Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism. Gut 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002;122(7):1778-83
   PubMed Web of Science ®Google Scholar
• Dinan TG, Quigley EM, Ahmed SM, et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006;130(2):304-11
   PubMed Web of Science ®Google Scholar
• Liebregts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007;132(3):913-20
   PubMed Web of Science ®Google Scholar
• Spivak B, Shohat B, Mester R, et al. Elevated levels of serum interleukin-1 beta in combat-related posttraumatic stress disorder. Biol Psychiatry 1997;42(5):345-8
   PubMed Web of Science ®Google Scholar
• Maes M, Lin AH, Delmeire L, et al. Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in posttraumatic stress disorder following accidental man-made traumatic events. Biol Psychiatry 1999;45(7):833-9
   PubMed Web of Science ®Google Scholar
• von Kanel R, Hepp U, Kraemer B, et al. Evidence for low-grade systemic proinflammatory activity in patients with posttraumatic stress disorder. J Psychiatr Res 2007;41(9):744-52
   PubMed Web of Science ®Google Scholar
• Gill J, Vythilingam M, Page GG. Low cortisol, high DHEA, and high levels of stimulated TNF-alpha, and IL-6 in women with PTSD. J Trauma Stress 2008;21(6):530-9
   PubMed Web of Science ®Google Scholar
• Li X, Kan EM, Lu J, et al. Combat-training increases intestinal permeability, immune activation and gastrointestinal symptoms in soldiers. Aliment Pharmacol Ther 2013;37(8):799-809
   PubMed Web of Science ®Google Scholar
• Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 2009;9(11):799-809
   PubMed Web of Science ®Google Scholar
• Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain 2009;146(1-2):41-6
   PubMed Web of Science ®Google Scholar
• Sun Y, Zhang M, Chen CC, et al. Stress-induced corticotropin-releasing hormone-mediated NLRP6 inflammasome inhibition and transmissible enteritis in mice. Gastroenterology 2013;144(7):1478-87. 1487 e1471-1478
   PubMed Web of Science ®Google Scholar
• Elinav E, Strowig T, Kau AL, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011;145(5):745-57
   PubMed Web of Science ®Google Scholar
• Park AJ, Collins J, Blennerhassett PA, et al. Altered colonic function and microbiota profile in a mouse model of chronic depression. Neurogastroenterol Motil 2013;25(9):733-e575
   PubMed Web of Science ®Google Scholar
• Xu D, Gao J, Gillilland M 3rd, et al. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology 2014;146(2):484-96.e4
   PubMed Web of Science ®Google Scholar
• Ait-Belgnaoui A, Han W, Lamine F, et al. Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: a possible action through interaction with epithelial cell cytoskeleton contraction. Gut 2006;55(8):1090-4
   PubMed Web of Science ®Google Scholar
• Eutamene H, Lamine F, Chabo C, et al. Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats. J Nutr 2007;137(8):1901-7
   PubMed Web of Science ®Google Scholar
• Holdeman LV, Good IJ, Moore WE. Human fecal flora: variation in bacterial composition within individuals and a possible effect of emotional stress. Appl Environ Microbiol 1976;31(3):359-75
   PubMed Web of Science ®Google Scholar
• Knowles SR, Nelson EA, Palombo EA. Investigating the role of perceived stress on bacterial flora activity and salivary cortisol secretion: a possible mechanism underlying susceptibility to illness. Biol Psychol 2008;77(2):132-7
   PubMed Web of Science ®Google Scholar
• Noor SO, Ridgway K, Scovell L, et al. Ulcerative colitis and irritable bowel patients exhibit distinct abnormalities of the gut microbiota. BMC Gastroenterol 2010;10:134
   PubMed Web of Science ®Google Scholar
• Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364(1):22-32
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010;59(3):325-32
   PubMed Web of Science ®Google Scholar